Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunoviaâ€™s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.

Employees

Sector

Advanced Medical Equipment & Technology

Calendar

Earnings release - Q2 2026

More about the company

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed OTC Markets Other stock markets 20:01:17 31/12/2025 +04			5-day change	1st Jan Change
2.000 ^USD	-48.56%		+9,900.00%	+9,900.00%

06-15	Immunovia Unveils New Data Ahead of Medicare Reimbursement Application	FW
06-15	Immunovia Announces New Performance Data for PancreaSure Ahead of Upcoming Application for Medicare Coverage	CI

Market Cap	124M 12.9M 11.27M 10.4M 9.59M 18.07M 1.24B 18.47M 48.89M 608M 48.43M 47.37M 2.09B	P/E 2026 *	-1.85x	P/E 2027 *	-4.62x
Enterprise Value	57.31M 5.95M 5.2M 4.79M 4.42M 8.33M 573M 8.51M 22.54M 280M 22.33M 21.84M 965M	EV / Sales 2026 *	17.9x	EV / Sales 2027 *	2.91x
Free-Float	89.3%	Yield 2026 *	-	Yield 2027 *	-

06-15	Immunovia Unveils New Data Ahead of Medicare Reimbursement Application	FW
06-15	Immunovia Announces New Performance Data for PancreaSure Ahead of Upcoming Application for Medicare Coverage	CI
06-10	Immunovia: Published study bolsters evidence for PancreaSure	FW
06-10	Immunovia Publishes Final Affirm Study Results in Journal of Clinical Oncology Confirming Strong Diagnostic Performance of Pancreasure	CI
05-07	Immunovia AB, Q1 2026 Earnings Call, May 07, 2026
05-07	Immunovia Q1 operating loss at SEK 18.4 mln	RE
05-07	Immunovia cash burn beats guidance - CEO: commercial pipeline significantly strengthened	FW
05-07	Immunovia AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-05	Immunovia launches registry study for PancreaSure	FW
05-05	Immunovia AB Launches Assure Registry To Evaluate Real-World Clinical Impact Of Pancreasure In High-Risk Pancreatic Cancer Surveillance	CI
04-10	Immunovia AB Auditor Raises 'Going Concern' Doubt	CI
03-23	96 stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
03-19	38 stocks hit new 52-week lows on Stockholm Stock Exchange so far today	FW

26/02/25	Carlsquare initiates assignment monitoring of Immunovia	FW
30/12/23	Bonesupport winner of the year and Viaplay loser of the year on Nasdaq Stockholm 2023	FW

Immunovia AB Stock OTC Markets

Stocks

IMMVF

SE0006091997

Advanced Medical Equipment & Technology

Valuation: Immunovia AB

Chart: Immunovia AB

Latest news : Immunovia AB

Last Transcript: Immunovia AB

Analysts' recommendations: Immunovia AB

Press Releases: Immunovia AB

Quotes and Performance

Course Extremes

Managers and Directors: Immunovia AB

Medical Diagnostic & Testing Equipment

Financials

Company Profile

Income Statement and Estimates

Quarterly revenue - Rate of surprise

1 day	-48.56%
1 week	+9,900.00%
Current month	+9,900.00%
1 month	+9,900.00%
3 months	+9,900.00%
6 months	+9,900.00%
Current year	+9,900.00%

Manager	Title	Age	Since
Jeff Borcherding CEO	Chief Executive Officer	53	29/04/2023
Lisa Ford CTO	Chief Tech/Sci/R&D Officer	55	29/04/2024
Norma Alonzo Palma CTO	Chief Tech/Sci/R&D Officer	54	31/01/2024

Director	Title	Age	Since
Hans Olof Gunnar Johansson BRD	Director/Board Member	72	09/12/2016
Peter Andersen CHM	Chairman	69	26/05/2023
Martin Brygger Møller BRD	Director/Board Member	51	01/01/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMMUNOVIA AB	-48.56%	+9,900.00%	-	-	12.9M
SARTORIUS AG	-2.49%	-4.65%	+17.60%	-26.78%	17.27B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+1.64%	-5.48%	+0.79%	+91.39%	1.57B
QUIDELORTHO CORPORATION	-0.60%	-3.75%	-31.94%	-79.70%	1.19B
ECKERT & ZIEGLER SE	+0.72%	-5.51%	-36.29%	+16.28%	999M
CONTEC MEDICAL SYSTEMS CO.,LTD	-0.64%	+2.18%	-28.81%	-52.65%	644M
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-1.79%	-5.76%	-41.68%	-57.20%	532M
VAREX IMAGING CORPORATION	+1.52%	-0.56%	+45.04%	-53.89%	445M
REVENIO GROUP OYJ	0.00%	-0.95%	-54.24%	-58.55%	382M
CELLAVISION AB	+1.09%	+7.51%	-14.58%	-31.90%	364M
Average	-4.92%	-1.79%	-16.01%	-28.11%	2.6B
Weighted average by Cap.	-1.77%	-0.35%	+7.88%	-22.23%

	2026 *	2027 *
Net sales	3.2M 332K 290K 268K 247K 465K 31.97M 475K 1.26M 15.66M 1.25M 1.22M 53.9M	17.3M 1.79M 1.57M 1.45M 1.33M 2.51M 173M 2.57M 6.8M 84.65M 6.74M 6.59M 291M
Net income	-91M -9.44M -8.25M -7.61M -7.02M -13.23M -909M -13.52M -35.79M -445M -35.46M -34.68M -1.53B	-82M -8.51M -7.43M -6.86M -6.32M -11.92M -819M -12.18M -32.25M -401M -31.95M -31.25M -1.38B
Net Debt	-67M -6.95M -6.07M -5.61M -5.17M -9.74M -669M -9.95M -26.35M -328M -26.11M -25.53M -1.13B	-74M -7.68M -6.71M -6.19M -5.71M -10.76M -739M -10.99M -29.11M -362M -28.83M -28.2M -1.25B

1 year	0.02	0.02
3 years	0.02	0.17
5 years	0.02	40
10 years	0.02	40